Skip to main content

Press Releases

Date Title
Toggle Summary Sienna Biopharmaceuticals Engages Cowen to Explore Financial and Strategic Alternatives
WESTLAKE VILLAGE, Calif. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives
Toggle Summary Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
WESTLAKE VILLAGE, Calif. , June 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the
Toggle Summary Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the results of its
Toggle Summary Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe
WESTLAKE VILLAGE, Calif. , May 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Paul F. Lizzul , M.D., Ph.D., Chief Medical Officer, and Silvio Traversa , B.Sc., Ph.D., Chief Scientific Officer, are

SEC Filings

Filer Filing date Form Filing Group View
8-K
Current Reports
View HTML
Beddingfield III Frederick 4
Section 16 Filings (3,4,5)
View HTML
Azoy Alexander 4
Section 16 Filings (3,4,5)
View HTML
Andrews Timothy K. 4
Section 16 Filings (3,4,5)
View HTML

Events

Webcast events that have already occurred are presented for historical purposes only and speak only as of the date thereof.

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

Firm Analyst
J.P. Morgan
Chris Schott
Cowen
Ken Cacciatore
BMO Capital Markets
Gary Nachman

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Transfer Agent

EQ Shareowner Services
www.shareowneronline.com

IR Contact

IR@SiennaBio.com

Media Contact

media@SiennaBio.com